ArticleStem cell research & therapy2026
Hydrogels modified with IL4 or SDF1 mimicking peptides serve as a supportive environment for human iPSC-derived myoblasts.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundSkeletal muscles are characterised by substantial regenerative potential, which may be insufficient in case of, e.g., extensive muscle damage, changes accompanying muscle diseases or ageing. For this reason, different ideas are being tested to develop efficient and safe approaches to treat such muscles. Among them, strategies based on biomaterials and stem cells or their derivatives play an important role.
methodsIn the current study, we tested RADA16-I-based hydrogels, modified with custom-designed IL4 or SDF1 mimicking peptides, as a tool that allows development, maintenance or even an increase of myogenic differentiation potential of human myoblasts derived from induced pluripotent stem cells (iPSCs), which are considered a source of cells in therapies for skeletal muscles. Since the release of abovementioned peptides from hydrogels requires activity of metalloproteinases (MMPs) we first assessed the expression of MMPs in iPSC-derived myoblasts cultured on hydrogels. Then we determined the influence of hydrogels on proliferation, apoptosis, and differentiation of iPSC-derived myoblasts as well as their transcriptome and secretome.
resultsWe found that the hydrogels designed by us allowed proper proliferation, migration, and myogenic differentiation of hiPSC-derived myoblasts. The latter was even increased in case of hydrogels functionalised with either IL4 or SDF1 peptides. Importantly, none of the hydrogels tested induced neither apoptosis nor unwanted differentiation, i.e. adipogenic, chondrogenic or osteogenic, of hiPSC-derived myoblasts. In response to hydrogel presence, changes in the expression of factors, such as CXCL8, FREM2, ADAMTS16, CDH9, IRS4, FIBIN, or MLIP involved in angiogenesis, inflammatory mediation, cell adhesion, neurogenesis, and regulation of myogenic program were observed.
conclusionsObtained results indicate that hydrogels functionalised with IL4 or SDF1 peptides serve as a supportive environment for myoblasts derived from hiPSCs and increase features that are beneficial for myogenic/regenerative potential of these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.